cMET
Showing 1 - 25 of 260
NSCLC, Other Solid Tumors Trial in Australia (GB263T)
Recruiting
- NSCLC
- Other Solid Tumors
- GB263T
-
Saint Leonards, New South Wales, Australia
- +3 more
Aug 3, 2022
Advanced Solid Tumors Which Are cMET-dependent Trial in Worldwide (Capmatinib, Nazartinib, Gefitinib)
Recruiting
- Advanced Solid Tumors Which Are cMET-dependent
- Capmatinib
- +3 more
-
Boston, Massachusetts
- +12 more
Jan 27, 2023
cMET Dysegulation Advanced Solid Tumors Trial in Worldwide (INC280)
Completed
- cMET Dysegulation Advanced Solid Tumors
-
Indianapolis, Indiana
- +16 more
Dec 16, 2020
cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, Midazolam, Caffeine)
Completed
- cMET-dysregulated Advanced Solid Tumors
- INC280
- +2 more
-
Atlanta, Georgia
- +11 more
Dec 8, 2020
cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, digoxin, rosuvastatin)
Completed
- cMET-dysregulated Advanced Solid Tumors
- INC280
- +2 more
-
Atlanta, Georgia
- +14 more
Dec 8, 2020
Advanced Solid Malignancies Trial in Worldwide (Ami-LC-MD, Ami-LC, Ami-HC)
Recruiting
- Advanced Solid Malignancies
- Ami-LC-MD
- +4 more
-
West Hollywood, California
- +13 more
Jan 31, 2023
Non Small Cell Lung Cancer Trial in Worldwide (Capmatinib, Nazartinib)
Terminated
- Non Small Cell Lung Cancer
-
Boston, Massachusetts
- +18 more
Jul 20, 2022
Malignant Melanoma, Breast Cancer Trial in Philadelphia (T cells modified with RNA anti -cMET CAR)
Terminated
- Malignant Melanoma
- Breast Cancer
- T cells modified with RNA anti -cMET CAR
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Mar 30, 2020
NSCLC Trial in Worldwide (INC280 (capmatinib))
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- INC280 (capmatinib)
-
Long Beach, California
- +95 more
Dec 29, 2022
Solid Tumor, Colorectal Cancer Trial in Oxford (PF-02341066, PD-0325901, Binimetinib)
Completed
- Solid Tumor
- Colorectal Cancer
- PF-02341066
- +2 more
-
Oxford, United KingdomOxford University Hospital NHS Trust
Jun 14, 2021
Non Small Cell Lung Cancer Trial in Worldwide (EGF816, INC280, Nivolumab)
NSCLC Trial in Worldwide (INC280 single agent, erlotinib)
Terminated
- Non-Small Cell Lung Cancer
- INC280 single agent
- erlotinib
-
Los Angeles, California
- +31 more
Feb 20, 2020
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
NAD Trial in Berlin (Niagen, Placebo)
Not yet recruiting
- NAD
- Niagen
- Placebo
-
Berlin, GermanySurgical Clinic, Campus Virchow-Klinikum / Campus Charité Mitte,
Aug 22, 2023
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- FPI-2053
- +2 more
-
Irvine, California
- +2 more
Nov 27, 2023
Obesity Trial in Mexico City (Ketogenic diet, Caloric restriction diet, Intermittent fasting 16/8)
Recruiting
- Obesity
- Ketogenic diet
- +2 more
-
Mexico City, MexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Aug 8, 2022
Time Restricted Feeding Trial in Nottingham (Short 10hr fast, Long 16h fast)
Recruiting
- Time Restricted Feeding
- Short 10hr fast
- Long 16h fast
-
Nottingham, Nottinghamshire, United KingdomUniversity of Nottingham
Jun 14, 2022
Chronic Venous Insufficiency Trial in Izmir (Training group: Inspiratory muscle training, Control group: Thoracic expansion
Not yet recruiting
- Chronic Venous Insufficiency
- Training group: Inspiratory muscle training
- Control group: Thoracic expansion exercise
-
İzmir, TurkeyIzmir Democracy University
Aug 5, 2023
Bromhidrosis Trial in Gent (Bacterial spray)
Recruiting
- Bromhidrosis
- Bacterial spray
-
Gent, BelgiumGhent University
Nov 30, 2022